Skip to main content

Table 5 Emergence of PA/I38X-substituted influenza virus

From: Baloxavir safety and clinical and virologic outcomes in influenza virus-infected pediatric patients by age group: age-based pooled analysis of two pediatric studies conducted in Japan

Influenza virus type (subtype)

PA/I38X-substituted virus

< 6 years

% (n/N)

≥6 to < 12 years

% (n/N)

A(H1N1)pdm09

 ITTI population

11.1 (1/9)

0.0 (0/4)

 Patients with paired sequence data

20.0 (1/5)

0.0 (0/2)

A(H3N2)

 ITTI population

44.4 (12/27)

14.5 (10/69)

 Patients with paired sequence data

52.2 (12/23)

18.9 (10/53)

B

 ITTI population

0.0 (0/16)

0.0 (0/4)

 Patients with paired sequence data

0.0 (0/13)

0.0 (0/3)

  1. ITTI intention-to-treat infected, PA/I38X polymerase acidic protein variant at position I38